期刊文献+

HCMV截短UL83基因真核表达重组体的构建、转染及其免疫效力研究 被引量:2

Construction and transfection of eucaryotic expression recombinant vector containing truncated region of UL83 gene of human cytomegalovirus and it's sheltered effect as DNA vaccine
在线阅读 下载PDF
导出
摘要 为了构建人巨细胞病毒(HCMV)截短UL83基因真核表达重组体,实现其在Hep-2细胞中的稳定表达,研究该截短UL83基因真核表达重组体免疫效力,采用基因重组的方法,将HCMVAD169株截短UL83基因定向克隆到带有绿色荧光蛋白(GFP)作为报告基因的真核表达载体pEGFP-C1上,构建真核重组表达质粒pEGFP-C1-UL83;脂质体转染至Hep-2细胞中,G418筛选获得稳定表达pp65细胞表达系。经基因测序屁示,重组体中截短UL83基因完全正确。RT-PCR和Westem blot检测证实其可在Hep-2细胞中稳定表达。用该重组体和其表达产物在HCMV先天性感染小鼠模型上进行免疫保护试验显示,母鼠血清可检测到特异性抗HCMVpp65抗体,效价为:1:2.51~1:50.79;子鼠脑组织内未分离出病毒,亦未检测出病毒pp65蛋白抗原表达。初步结果表明,pEGFP-C1-UL83具有较好的免疫原性,可作为DNA疫苗刺激机体产生有效抗体。并具有阻止病毒垂直传播的保护性作用。 To construct eucaryotic expression recombinant vector containing vivo truncated region of UL83 gene of human cytomegalovirus, realize its steady expression in Hep-2 cell, and study sheltered effect of the eucaryotic expression recombinant vector as DNA vaccine. A vivo truncated UL83 gene fragment encoding for truncated HCMV pp65 was obtained by PCR from human cytomegalovirus AD169 stock genome. By gene recombinant ways, the truncated UL83 gene fragment was cloned into eucaryotic expression vector pEGFP-C1 with reported gene coding GFP to construct recombinant vector pEGFP-CI-UL83. The recombinant vector pEGFP-C1-UL83 was tested by different methods including PCR, restriction digestion and gene sequencing. Test results showed the recombinant vector was constructed successfully. After pEGFP-C1-UL83 was transfected into Hep-2 cell by lipofectin mediation, expression of GFP and truncated pp65 fusion protein in Hep-2 cell was observed at different time points by fluorescence microscope. Results showed that quantity of fusion protein expression was the highest at 36h point. Then, Hep-2 cell was cultured selectively by RPMI-1640 containing G418 (200μg/mL) to obtain a new cell stock of expressing truncated UL83 Gene fragment steadily. RT-PCR and Western blot results showed the truncated fragment of UL83 gene could be expressed steadily in Hep-2 cell. The result showed a new cell stock of expressing Tpp65 was established. This cell stock could be useful in some HCMV research fields, for example, it could be a tool in study of pp65 and HCMV infection, and it could provide a platform for the research into the therapy of HCMV infection. Immune sheltered effect of pEGFP-C1-UL83 as DNA vaccine was studied in vivo of HCMV congenital infection mouse model. The mouse model was immunized solely by pEGFP-C1-UL83, and was immunized jointly by pEGFP-C1-UL83 and its expression product. When the mouse was pregnant and brought to bed, differential antibody of anti-HCMV pp65 was tested by indirect ELISA in mother mouse, the infectious virus was separated with the method of virus separation, and pp65 antigen was checked up by indirect immunofluorescence staining in fetal mouse. Results showed differential antibody of anti-HCMV pp65 was produced in mouse model. Tilter of the antibody was from 1:2.51 to 1:50.79. Results of virus separation and pp65 checkup of fetal mouse brain tissue were negative. So the conclusion can be reached that pEGFP-C1-UL83 as DNA vaccine in vivo has sheltered effect which can prevent HCMV vertical transmission from mother mouse to her fetus.
出处 《微生物学报》 CAS CSCD 北大核心 2006年第3期451-455,T0001,共6页 Acta Microbiologica Sinica
基金 安徽省科技厅"十五"生物医药重大科技专项(01303003) 教育部科学技术研究重点项目(01052)~~
关键词 HCMV截短uL83基因 绿色荧光蛋白 转染 HEP-2细胞 DNA疫苗 Human cytomegalovirus(HCMV) Truncated region of UL83 Gene Green fluorescence protein (GFP) Transfection Hep-2 cell DNA vaccine
  • 相关文献

参考文献16

  • 1Sweet C.The pathogenicity of cytomegalovirus.FEMS Microbiol Rev,1999,23(4):457-482.
  • 2Schmolke S,Drescher P,Jahn G,et al.Nuclear targeting of the tegument protein pp65 (UL83) of human cytomegalovirus:an unusual bipartite nuclear localization signal functions together with other portions of the protein to mediate its efficient nuclear transport.J Virol,1995,69:1071-1078.
  • 3Wills MR,Carmichael A,Mynard K,et al.The human cytotoxic T-lymphocyte (CTL) response to cytomegalavirus is dominated by structureal protein pp65:frequency,specificity,and T-cell receptor usage of pp65-specific CTL.J Virol,1996,70(11):7569-7579.
  • 4Beninga J,Kropff B,Mach M,et al.Comparative analysis of fourteen individual HCMV protein for helper T cell response.J Gen Virol,1995,76:153-160.
  • 5Weekes MP,Wills MR,Mynard K,et al.The memory cytoxic T-lymphcyte(CTL) response to human cytomegalovirus infection contains individual peptide-specific CTL clones that have undergone extensive expansion in vivo.J Virol,1999,73(3):2099-2108.
  • 6Zal B,Booth J,Chadwick J,et al.Epitope mapping of mouse monoclonal antibodies to the ppUL83 lower matrix phosphoprotein of human cytomegalovirus.J Medical Virol,1999,57:290-297.
  • 7Li PG,Bottone L,Ivaldi F,et al.Recognition of CMV pp65 protein antigen by human CD4 T-cell lines induced with an immunodominant peptide pool.Hum Immunol,2004,65:537-543.
  • 8Paston SJ,Dodi IA,Madrigal JA.Progress made towards the development of a CMV peptide vaccine.Humane Immunnology,2004,65:544-549.
  • 9王明丽,唐久来,胡闻,史百芬,胡勇,毕克菊,李京培.人巨细胞病毒先天性中枢神经系统感染小鼠模型的建立[J].动物学报,2000,46(2):167-174. 被引量:20
  • 10李昂,张晓实,王鸿鹤,姜桔红,刘晓琼,刘启才,曾益新.Epstein-Barr病毒A73基因在鼻咽癌组织中的表达及其细胞内定位研究[J].癌症,2003,22(6):597-601. 被引量:5

二级参考文献14

  • 1王明丽,曹慧,史百芬,李京培,张广民,聂红先,何家艾.特发性血小板减少性紫癜与HCMV活动性感染[J].安徽医科大学学报,1996,31(1):16-18. 被引量:10
  • 2李天宪,赵林,冯锋,陈绳亮,夏萍.人巨细胞病毒小鼠模型的建立[J].微生物学报,1996,36(4):292-294. 被引量:22
  • 3[1]Nieboditek G. The Epstein- Barr virus:a group 1 carcinogen? [J]. Virchow Arch,1999,435:79- 86.
  • 4[2]Brooks LA, Lear AL, Young LS, et al. Transcripts from the Epstein- Barr virus BamHⅠ A fragment are detectable in all three forms of virus latency [J]. J Virol,1993,67(6): 3182- 3190.
  • 5[3]Chen HL,Lung MM,Sham JS,et al. Transcription of BamHⅠ A region of the EBV genome in NPC tissues and B cells [J]. Virology,1992,191:193- 201.
  • 6[4]Gilligan KJ,Rajadurai P,Lin JC,et al. Expression of the Epstein- Barr virus BamHⅠ A fragment in nasopharyngeal carcinoma:evidence for a virus protein expressed in vivo [J]. J Virol,1991,65(11):6252- 6259.
  • 7[5]Imai S,Nishikawa J,Takada J. Cell- to- cell contact as an efficient mode of Epstein- Barr virus infection of diverse human epithelial cells[J]. J virol,1998,72:4371- 4378.
  • 8[6]Karran L,Gao Y,Smith PR,et al. Expression of a family of complementary- strand transcripts in Epstein- Barr virus- infected cells [J]. Proc Natl Acad Sci USA,1992, 89:8058- 8062.
  • 9[7]Chen H,Smith P, Ambinder RF,et al. Expression of Epstein- Barr virus BamHI A rightward transcripts in Latently infected B cells from peripheral blood [J]. Blood,1999, 93(9):3026- 3032.
  • 10[8]Smith PR,de Jesus O,Turner D,et al. Structure and coding content of CST(BARTs) family RNAs of Epstein- Barr virus [J]. J Virol,2000,74(7):3082- 3092.

共引文献22

同被引文献31

  • 1李雪丹,金红.先天巨细胞病毒感染致畸机制研究进展[J].国外医学(病毒学分册),2004,11(4):128-128. 被引量:15
  • 2胡大林,庄志雄,刘移民,何云,纪卫东,方道奎,沙焱,涂晓志,杨建平.载体介导的人支气管上皮细胞DNA聚合酶β基因的靶向RNA干扰[J].卫生研究,2006,35(2):143-145. 被引量:3
  • 3孙兆明,于士柱,张文治,康春生,周宏旭,黄慧玲,安同岭.生长抑制因子1基因核定位序列绿荧光蛋白融合表达载体的构建及表达[J].中华医学遗传学杂志,2006,23(3):330-332. 被引量:2
  • 4孔德升,郭泓珅,蔡旭,梁旺,彭卓醇,宋后燕,马端.hTFPI-2的基因克隆表达及生物学性质研究[J].中华血液学杂志,2006,27(9):606-610. 被引量:4
  • 5Eryol NK, Kilie H, Gul A, et al. Are the high levels of eytomegalovirus antibodies a determinant in the development of coronary artery disease? Int Heart J ,2005,46(2) : 205-219.
  • 6Castillo JP, Frame FM, Rogoff HA, et al. Human cytomegalovirus IE1-72 activates ataxia telangiectasia mutated kinase and a p53/p21-mediated growth arrestresponse. Virology, 2005,79(17):11467-11475.
  • 7Kim J, Kwon YJ, Park ES, et al. Human cytomegalovirus(HCMV) IE1 plays role in resistance to apoptosis with etoposide in cancer cell line by Cdk2 accumulation. Microbiol Immunol, 2003,47 (12):959-967.
  • 8Elek SD, Stern H. Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero.Lancet, 1974,i(7845) : 1-5.
  • 9Adler SP, Hempfling SH,Starr SE,et al. Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. Pediatr Infect Dis J,1998,17(3) :200-206.
  • 10Schleiss M. Progress in cytomegalovirus vaccine development.Herpes ,2005,12(3) : 66-75.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部